OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer

Abstract c-MET is considered a driver of cancer progression, impacting tumor growth and tumor-supporting stroma. Here, we investigated the therapeutic efficacy of OMO-1, a potent and selective c-MET inhibitor, in an immunocompetent intraductal mouse model for triple-negative breast cancer (TNBC). OM...

Full description

Saved in:
Bibliographic Details
Main Authors: Jonas Steenbrugge, Niels Vander Elst, Kristel Demeyere, Olivier De Wever, Niek N. Sanders, Wim Van Den Broeck, Eric Ciamporcero, Timothy Perera, Evelyne Meyer
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Online Access:https://doaj.org/article/b9aac903f53b496da8763625e4385c99
Tags: Add Tag
No Tags, Be the first to tag this record!